1Plwa JL, Britta E ,Jayne L,et al Targeting Rat Anti-Mouse Transferrrin Receptor Monoclonal antibody through Blood -Brain Barrier in Mouse. [ J ]. J pharmacology and experiment therapeutics. 2000,292,1048-1057.
2Remsen LG. Enhanced delivery improves the efficacy of a tumorspecific doxorubicin immunoconjugate in a human brain tumor xenograft model. [ J ]. Neurosurgery, 2000,46 ( 3 ) :704-709.
3Sjogren HO, Isaksson Willner D ,et al. Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats [ J]. Cancer Res, 1997,57: 4530-4536.
4Lode HN, Reisfeld RA, Handgretinger, Nicolaou, G Ga. et al. Targeted therapy with a novel enediyene antibiotic calicheamicin theta(I) 1 effectively suppresses growth and dissemination of liver metastases in a syngeneic model of murine neuroblastoma. [ J ]. Cancer Res, 1998,58 : 2925-2928.
5Katrin K, Wolfgang W, Jürgen E. et al. Targeted Therapy of Experimental Renal Cell Carcinoma with a Novel Conjugate of Monoclonal Antibody 138H11 and Calicheamicin I1 [J]. Cancer Res,2000,60 : 6089-6094.
6Véronique and H. Uri Saragovi,Taxane-Antibody Conjugates Afford Potent Cytotoxicity, Enhanced Solubility, and Tumor Target Selectivity[J]. Cancer Res 2001 61 : 694-699.
7Vogel CA, Galmiche MC, Buchegger F, Radioimmunotherapy and fractionated radiotherapy of human colon cancer liver metastases in nude mice [ J ]. Cancer Res, 1997,57 : 447 -453.
8Robert T, Sally J. Aina, et al. Meyers Radioimmunotherapy with 111In/90Y-2IT-BAD-ml70 for Metastatic Prostate Cancer [ J ].Clin Cancer Res,2001,7 : 1561-1568.
9Lee H. Jacy V, hepatotoxicity incancer patients receiving erb-38, a recombinant immunotoxi that targets the erb2 receptor [ J ]. Clin Cancer Res, 1999,5:2311-2315.
10Kreitman R J,Wilson W H,Bergeron K,et al. Efficacy of the Anti-CD22 Recombinant Immunotoxin BL22 in Chemotherapy-Resistant Hairy-Cell Leukemia[J]. N Engl J Med,2001,345 : 241-247.
